Switch theme
Sign up to access all valuation multiples
Luyan Pharma Co Ltd, formerly Luyan (Fujian) Pharma Co Ltd engages in the production, operation, distribution, and retail of human health products in China. It provides medical and health products.
2008
n/a
Last FY Revenue $2.8B
Last FY EBITDA $110M
$1.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Luyan Pharma achieved revenue of $2.8B and an EBITDA of $110M.
Luyan Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Luyan Pharma valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $2.8B | XXX | XXX | XXX |
| Gross Profit | XXX | $212M | XXX | XXX | XXX |
| Gross Margin | XXX | 7% | XXX | XXX | XXX |
| EBITDA | XXX | $110M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 4% | XXX | XXX | XXX |
| EBIT | XXX | $95.9M | XXX | XXX | XXX |
| EBIT Margin | XXX | 3% | XXX | XXX | XXX |
| Net Profit | XXX | $48.0M | XXX | XXX | XXX |
| Net Margin | XXX | 2% | XXX | XXX | XXX |
| Net Debt | XXX | $548M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Luyan Pharma's stock price is CNY 8 (or $1).
Luyan Pharma has current market cap of CNY 3.3B (or $452M), and EV of CNY 7.9B (or $1.1B).
See Luyan Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.1B | $452M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Luyan Pharma has market cap of $452M and EV of $1.1B.
Luyan Pharma's trades at 0.4x EV/Revenue multiple, and 10.0x EV/EBITDA.
Equity research analysts estimate Luyan Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Luyan Pharma's P/E ratio is not available.
See valuation multiples for Luyan Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $452M | XXX | $452M | XXX | XXX | XXX |
| EV (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 0.4x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 10.0x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 11.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 9.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 36.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLuyan Pharma's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Luyan Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Luyan Pharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Luyan Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 4% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| SC Ropharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Luyan Pharma acquired XXX companies to date.
Last acquisition by Luyan Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Luyan Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Luyan Pharma founded? | Luyan Pharma was founded in 2008. |
| Where is Luyan Pharma headquartered? | Luyan Pharma is headquartered in China. |
| Is Luyan Pharma publicy listed? | Yes, Luyan Pharma is a public company listed on SHE. |
| What is the stock symbol of Luyan Pharma? | Luyan Pharma trades under 002788 ticker. |
| When did Luyan Pharma go public? | Luyan Pharma went public in 2016. |
| Who are competitors of Luyan Pharma? | Similar companies to Luyan Pharma include e.g. MedPlus India, SC Ropharma, Pague Menos, Droga Raia. |
| What is the current market cap of Luyan Pharma? | Luyan Pharma's current market cap is $452M |
| Is Luyan Pharma profitable? | Yes, Luyan Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
